Premium
Potential emerging treatment in vitiligo using Er: YAG in combination with 5 FU and clobetasol
Author(s) -
Mokhtari Fatemeh,
Bostakian Anis,
Shahmoradi Zabihollah,
JafariKoshki Tohid,
Iraji Fariba,
Faghihi Gita,
Hosseini Sayed Mohsen,
Bafandeh Behzad
Publication year - 2018
Publication title -
journal of cosmetic dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.626
H-Index - 44
eISSN - 1473-2165
pISSN - 1473-2130
DOI - 10.1111/jocd.12373
Subject(s) - vitiligo , dermatology , medicine
Summary Background Vitiligo is a pigmentary disorder of skin affecting at least 1% of the world population of all races in both sexes. Its importance is mainly due to subsequent social and psychological problems rather than clinical complications. Various treatment choices are available for vitiligo; however, laser‐based courses have shown to give more acceptable results. Objective The aim of this trial was to evaluate the efficacy of Er: YAG laser as a supplementary medicine to topical 5 FU and clobetasol in vitiligo patients. Methods Two comparable vitiligo patches from 38 eligible patients were randomized to receive topical 5 FU and clobetasol in control group and additional Er: YAG laser in intervention group. Major outcomes of interest were the size of patch and pigmentation score at randomization and 2 and 4 months after therapy. Results Final sample included 18 (47%) male patients and age of 35.66±8.04. The performance Er: YAG group was superior in all sites. Reduction in the size of patches was greater in Er: YAG group ( p ‐value=.004). Also, this group showed a higher pigmentation scores in the trial period than control group ( p ‐value<.001). Conclusions Greater reduction in the size and increase in pigmentation score was seen in Er: YAG group especially for short periods after therapy and repeating laser sessions may help improving final outcomes. Er: AYG could help in reducing complications of long‐term topical treatments, achieving faster response, and improving patient adherence.